Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

IMTX Stock  USD 7.18  0.09  1.24%   
Slightly above 62% of Immatics' investor base is looking to short. The analysis of the overall investor sentiment regarding Immatics NV suggests that many traders are alarmed. Immatics' investing sentiment can be driven by a variety of factors including economic data, Immatics' earnings reports, geopolitical events, and overall market trends.
  
Houston, Texas and Tuebingen, Germany, October 4, 2024 Immatics N.V. , a clinical-stage biopharmaceutical...

Read at globenewswire.com
Macroaxis News: globenewswire.com
  

Immatics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Immatics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Immatics Fundamental Analysis

We analyze Immatics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immatics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

Immatics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Immatics NV Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immatics stock to make a market-neutral strategy. Peer analysis of Immatics could also be used in its relative valuation, which is a method of valuing Immatics by comparing valuation metrics with similar companies.

Peers

Immatics Related Equities

EWTXEdgewise Therapeutics   18.36   
0%
100.0%
ALXOAlx Oncology   16.23   
0%
88.0%
MRUSMerus BV   4.91   
0%
26.0%
FENCFennec Pharmaceuticals   2.02   
0%
11.0%
HRMYHarmony Biosciences   1.72   
0%
9.0%
MLYSMineralys Therapeutics,   1.56   
0%
8.0%
CRNXCrinetics Pharmaceuticals   1.35   
0%
7.0%
AVTEAerovate Therapeutics   1.19   
0%
6.0%
INBXInhibrx   0.07   
1.0%
0%
REPLReplimune   0.56   
3.0%
0%
SNDXSyndax Pharmaceuticals   1.16   
6.0%
0%
KRONKronos Bio   2.04   
11.0%
0%
BCABBioatla   2.96   
16.0%
0%
LYELLyell Immunopharma   2.99   
16.0%
0%
JANXJanux Therapeutics   3.17   
17.0%
0%
KROSKeros Therapeutics   7.31   
39.0%
0%

Additional Tools for Immatics Stock Analysis

When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.